THERAPEUTIC DRUG MONITORING OF INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES: REAL-LIFE DATA IN A COHORT OF PATIENTS

被引：0
|
作者：
Martin Lopez, M. [1 ]
Molina Esteban, N. [1 ]
Cabrera, O. [2 ]
Pablos, J. L. [1 ]
机构：
[1] Hosp Univ 12 Octubre, Inst Invest i12, Rheumatol, Madrid, Spain
[2] Hosp Univ 12 Octubre, Immunol, Madrid, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Spondyloarthritis; bDMARD; Rheumatoid arthritis;
D O I：
10.1136/annrheumdis-2023-eular.4892
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0964
引用
收藏
页码：1700 / 1701
页数：2
相关论文
共 50 条
  • [1] The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
    Chenglong Han
    Josef S Smolen
    Arthur Kavanaugh
    Désirée van der Heijde
    Jürgen Braun
    René Westhovens
    Ning Zhao
    Mahboob U Rahman
    Daniel Baker
    Mohan Bala
    Arthritis Research & Therapy, 9
  • [2] Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases
    Bruni, Cosimo
    Bitti, Roberta
    Nacci, Francesca
    Cometi, Laura
    Tofani, Lorenzo
    Bartoli, Francesca
    Fiori, Ginevra
    Matucci-Cerinic, Marco
    CLINICAL RHEUMATOLOGY, 2021, 40 (01) : 85 - 91
  • [3] Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases
    Cosimo Bruni
    Roberta Bitti
    Francesca Nacci
    Laura Cometi
    Lorenzo Tofani
    Francesca Bartoli
    Ginevra Fiori
    Marco Matucci-Cerinic
    Clinical Rheumatology, 2021, 40 : 85 - 91
  • [4] Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study
    Flipo, R. -M.
    Tubach, F.
    Goupille, P.
    Lespessailles, E.
    Harid, N.
    Sequeira, S.
    Bertin, P.
    Fautrel, B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (03) : 537 - 545
  • [5] Therapeutic consequences in patients with both inflammatory rheumatic diseases and multiple sclerosis
    Letarouilly, Jean-Guillaume
    Vermersch, Patrick
    Flipo, Rene-Marc
    RHEUMATOLOGY, 2023, 62 (07) : 2352 - 2359
  • [6] Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study
    Dumusc, Alexandre
    Alromaih, Fahad
    Perreau, Matthieu
    Huegle, Thomas
    Zufferey, Pascal
    Dan, Diana
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [7] Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study
    Alexandre Dumusc
    Fahad Alromaih
    Matthieu Perreau
    Thomas Hügle
    Pascal Zufferey
    Diana Dan
    Arthritis Research & Therapy, 25
  • [8] Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease
    Gibson, David J.
    Ward, Mark G.
    Rentsch, Clarissa
    Friedman, Antony B.
    Taylor, Kirstin M.
    Sparrow, Miles P.
    Gibson, Peter R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (06) : 612 - 628
  • [9] Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases
    Paintaud, Gilles
    Passot, Christophe
    Ternant, David
    Bertolotto, Antonio
    Bejan-Angoulvant, Theodora
    Pascual-Salcedo, Dora
    Mulleman, Denis
    THERAPEUTIC DRUG MONITORING, 2017, 39 (04) : 339 - 343
  • [10] Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry
    Kvamme, Maria K.
    Lie, Elisabeth
    Kvien, Tore K.
    Kristiansen, Ivar S.
    RHEUMATOLOGY, 2012, 51 (09) : 1618 - 1627
12345